MedTrace Logo

Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)

NCT02988362 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-04-04

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and pharmacokinetics of HL068 (Candesartan 16 mg and Amlodipine 10mg) with coadministration of the two separate drugs in healthy male volunteers.

Conditions

Interventions

DRUG

HL068 16/10mg

Candesartan 16mg and Amlodipine 10mg

DRUG

Candesartan 16mg and Amlodipine 10mg

Sponsors & Collaborators

  • HanAll BioPharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Young-Ran Yoon, M.D, Ph.D · KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL CLINICAL TRIAL CENTER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-14
Primary Completion
2017-02-04
Completion
2017-02-04

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02988362 on ClinicalTrials.gov